This is an application of a Program Project Grant (P01) for a coordinated, multi-disciplinary investigation of the cellular and molecular mechanisms of immune responses to red blood cell (RBC) transfusion. Though often lifesaving, transfusions can also lead to RBC alloimmunization, whereby anti-RBC alloantibodies can ultimately result in both Delayed Hemolytic Transfusion Reactions and/or Hemolytic Disease of the Fetus and Newborn, leading to morbidity and in some cases mortality. In addition, large quantities of human epidemiological data indicate that alloantigens on RBCs represent a distinct immune stimulus with a pattern of recipient responses that differs substantially from better studied scenarios of immunization. Currently, our understanding of how transfused RBCs drive immune responses (or fail to do so) remains limited. Herein we propose an extensive collaborative program entitled Immunobiology of Transfusion aimed at employing innovative and cutting edge pre-clinical models and immunological tools, combined with human studies, to experimentally determine the molecular and cellular pathways that regulate RBC alloimmunization. The proposed program consists of four projects and two cores. The principal investigator and project leaders are all physician-scientists with formal basic science training in immunology and also with a clinical focus on transfusion medicine. Moreover, while this is an application for a new program, it builds upon a decade of collaborative work by the applicant investigators, providing a historical basis for synergistic collaboration. Project 1 will investigate mechanisms by which antibodies to RBCs regulate alloimmunization as a model to study anti-RhD immune prophylaxis. Tested hypotheses include cellular mechanisms of anti-RBC immunoregulation, molecular investigations of the role of IgG subtypes, and Fc?R biology. Project 2 will focus on investigation of the role of marginal zone B cells in RBC alloimmunization, studying both human volunteers and patients with sickle cell disease. Project 3 will investigate which innate immune receptors are activated by transfused RBCs and are functionally required for T cell dependent RBC alloantibody generation with a focus on MyD88-driven cellular responses, identification of Toll like receptors involved, and cytokine networks. Project 4 will focus on the biology of follicular helper T cells and specific cytokine circuits, using pre-clinical models and studying patients with sickle cell disease. There are two supporting cores. Core A (administrative core) will oversee and coordinate the administrative, scientific, and fiscal operation of the program as well as providing biostatistics support to all projects. Core B (mouse blood center core) will set up a cost effective, centralized, quality controlled and standardized blood collection/processing center for generating units of mouse RBCs that will be used by all 4 projects. Collectively, this program will yield fundamental mechanistic and translational insights into how transfusion leads to RBC alloimmunization, provide a rational basis to develop new therapeutic interventions and also generate novel understanding of immunology, in general.
Transfusion of red blood cells is the single most common therapy given to patients today, with approximately 1 in every 70 Americans receiving a transfusion annually. However, when a transfusion recipient's immune system reacts to transfused red blood cells, it can render the recipient unable to receive therapy. The proposed project is focused on increasing our understanding of the immune response to red blood cell transfusion with the ultimate goal of developing therapies to prevent this problem.
| Howie, Heather L; Wang, Xiaohong; Kapp, Linda et al. (2018) Common murine immunoglobulin detection reagents have diminished reactivity with IgG3 - A vulnerability to misinterpretation. J Immunol Methods 455:10-13 |
| Maier, Cheryl L; Mener, Amanda; Patel, Seema R et al. (2018) Antibody-mediated immune suppression by antigen modulation is antigen-specific. Blood Adv 2:2986-3000 |
| Mener, Amanda; Patel, Seema R; Arthur, Connie M et al. (2018) Complement serves as a switch between CD4+ T cell-independent and -dependent RBC antibody responses. JCI Insight 3: |
| Mener, Amanda; Arthur, Connie M; Patel, Seema R et al. (2018) Complement Component 3 Negatively Regulates Antibody Response by Modulation of Red Blood Cell Antigen. Front Immunol 9:676 |
